Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Lenalidomide may stop the growth of prostate cancer by blocking blood flow to the
tumor. GM-CSF may stimulate the immune system in different ways and stop tumor cells from
growing. Giving lenalidomide together with GM-CSF may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of lenalidomide
when given together with GM-CSF and to see how well it works in treating patients with
prostate cancer.